These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14987267)

  • 1. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
    Fernandez-Galar M; España A; López-Picazo JM
    Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 3. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
    Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
    Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 5. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 7. [Acneiform eruption from epidermal growth factor receptor inhibitors].
    Martínez de Lagrán Z; Ratón JA; Lasa O; Acebo E; Díaz-Pérez JL
    Actas Dermosifiliogr; 2005 Sep; 96(7):450-4. PubMed ID: 16476273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Images in clinical medicine. Cetuximab-associated acneiform eruption.
    Moss JE; Burtness B
    N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
    [No Abstract]   [Full Text] [Related]  

  • 9. Cetuximab-induced acneiform eruption and the response to isotretinoin.
    Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
    Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
    [No Abstract]   [Full Text] [Related]  

  • 10. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
    Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B
    Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.
    Warthan MM; Jumper CA; Smith JL
    J Drugs Dermatol; 2004; 3(5):569-70. PubMed ID: 15552613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exfoliative eruption secondary to gefitinib (ZD1839).
    Becuwe C; Dalle S; Arpin D; Balme B; Thomas L
    Dermatology; 2007; 215(3):266-8. PubMed ID: 17823530
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
    Lee MW; Seo CW; Kim SW; Yang HJ; Lee HW; Choi JH; Moon KC; Koh JK
    Acta Derm Venereol; 2004; 84(1):23-6. PubMed ID: 15040473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
    Zhao Q; Wang YN; Wang B
    Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
    Pascual JC; Belinchón I; Sivera F; Yuste A
    Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma.
    Kovalyshyn I; Bijal AD; Lacouture ME; Brownell I
    J Am Acad Dermatol; 2011 Sep; 65(3):657-659. PubMed ID: 21839325
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.